Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2008
Accounting Basis: U.S. GAAP
Teva is a global pharmaceutical company and the leading generic drug company in the world and the United States. The company operates in three main segments: Pharmaceuticals (generic and branded), Active Pharmaceutical Ingredients (API), and Corporate/Other. A defining event of the period was the acquisition of Barr Pharmaceuticals, Inc. on December 23, 2008, for approximately $7.5 billion (including transaction costs), significantly expanding Teva's U.S. and European footprint. Barr's results of operations are not included in the 2008 income statement but are reflected in the balance sheet as of year-end.
Key Financial Metrics
| Metric (in millions USD) | 2008 | 2007 |
|---|---|---|
| Net Sales | 11,085 | 9,408 |
| Gross Profit | 5,968 | 4,877 |
| Gross Margin | 53.8% | 51.8% |
| Operating Income | 1,145 | 2,395 |
| Net Income | 635 | 1,952 |
| Diluted EPS | $0.78 | $2.38 |
| Operating Cash Flow | 3,231 | 1,813 |
| Total Assets | 32,904 | 23,412 |
| Total Debt (Short + Long Term) | 8,443 | 5,188 |
| Working Capital | 2,945 | 4,488 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% to $11.1 billion, driven by strong generic sales in the U.S., record new product launches, and growth in branded products (Copaxone, Azilect).
- Profitability Decline: Net income dropped 67% to $635 million. This decline was primarily due to non-recurring charges totaling approximately $1.8 billion, including:
- $1.4 billion write-off of in-process research and development (IPR&D) related to the Barr and CoGenesys acquisitions.
- $375 million charge for other-than-temporary impairment of financial assets (mainly auction rate securities).
- $107 million impairment of intangible assets.
- Expense Increases: R&D expenses rose 35% to $786 million as part of a strategic goal to double R&D output by 2012. Selling, General, and Administrative (SG&A) expenses increased 32% to $2.5 billion, partly due to assuming full distribution costs for Copaxone in North America.
- Balance Sheet Expansion: Total assets increased by $9.5 billion, largely due to the inclusion of Barr's assets. Goodwill increased to $12.3 billion.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- 2009 Expectations: Management anticipates significant expenses in 2009 related to the Barr acquisition, including a $270 million inventory step-up, $475 million in amortization of intangibles, and interest expenses of $200–$250 million.
- Non-GAAP Performance: Excluding acquisition-related charges and impairments, management reported Non-GAAP net income of $2.37 billion (EPS $2.86), representing a 22% increase over 2007.
- Strategic Goals: Teva aims to double its 2007 business size by 2012, targeting $20 billion in revenue and net income margins exceeding 20%.
Risks and Contingencies:
- Patent Litigation: Teva faces significant litigation risks regarding generic products launched prior to patent expiration (e.g., Neurontin, Protonix, Allegra). Adverse rulings could result in substantial damages or injunctions.
- Currency Fluctuations: A strong U.S. dollar in late 2008 negatively impacted operating profit and net income. Management expects currency headwinds to continue into 2009.
- Regulatory Environment: Changes in healthcare reimbursement (Medicaid/Medicare) and pricing regulations in Europe and Israel pose ongoing risks to margins.
- Intangible Asset Impairment: With significant goodwill and intangible assets on the balance sheet, future impairment charges remain a risk.
Key Facts for Investor Verification
- Barr Acquisition Integration: Verify the timeline and financial impact of integrating Barr Pharmaceuticals, specifically the $270 million inventory step-up and $475 million annual amortization expected in 2009.
- Non-GAAP Reconciliation: Review the reconciliation of GAAP net income ($635M) to Non-GAAP net income ($2.37B) to understand the magnitude of one-time charges.
- Auction Rate Securities: Confirm the current valuation and liquidity status of the remaining $450 million principal amount of auction rate securities, which were written down by $352 million.
- Copaxone Litigation: Monitor the status of the lawsuit filed by Sandoz/Momenta regarding a generic version of Copaxone, Teva's leading innovative product.
- Debt Servicing: Assess the company's ability to service increased debt levels ($8.4 billion total) and meet covenants following the Barr acquisition financing.